Therapy News and Research

RSS

Free nicotine patches to help smokers quit this New Year

British smokers thinking of quitting have a reason to celebrate this New Year. Free nicotine patches are to be offered on the NHS as part of a major drive to help smokers quit. The Department of Health has announced that smokers would be given coupons for a week’s free trial of the patches in the “Quit kits”. The patches included in the kit will be either NiQuitin Clear 21mg patches or Nicotinell TTS 30 21mg/24 hour patches, Step 1.

29 Dec 2010

Patients unresponsive to anti-anemia drug have higher risk of cardiovascular disease, death

Patients with diabetes, kidney disease and anemia who don't respond to treatment with an anti-anemia drug have a higher risk of cardiovascular disease or death, researchers at UT Southwestern Medical Center have found.

28 Dec 2010

International reference standards for use of bone turnover markers in clinical studies recommended

An expert working group of the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) has released a new position paper which reviews the evidence of bone turnover markers (BTMs) in fracture risk prediction and monitoring of osteoporosis therapy. More importantly, it identifies research priorities and recommends that specific markers be used as reference analytes for BTMs in clinical and observational studies.

28 Dec 2010

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

EpiCept Corporation today reported that Myrexis, Inc. has initiated a controlled two-arm Phase 2b clinical study of Azixa™ as a front-line treatment for glioblastoma multiforme (GBM). Azixa™, a vascular disruption agent with potent anti-cancer activity, was discovered by EpiCept as part of its ASAP technology platform and licensed to Myrexis.

28 Dec 2010

Biglycan protein offers potential therapy for muscular dystrophy

A novel potential therapy based on a natural human protein significantly slows muscle damage and improves function in mice who have the same genetic mutation as boys with the most common form of muscular dystrophy, according to a paper published online Dec. 27 in the Proceedings of the National Academy of Sciences.

28 Dec 2010

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Vicus Therapeutics, LLC, today announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia.

28 Dec 2010

Stem cell therapy helps patient with diabetes gangrene recover from foot ulcer: ICMS conference

During ICMS Annual International Congress on Regenerative and Cell Based Medicine Conference held on November 12, 2010 in Las Vegas, Nevada, it was announced that a patient with complications of diabetes gangrene recovered from foot ulcer through stem cell therapy.

27 Dec 2010

Sverica International acquires Center for Wound Healing

The Center for Wound Healing, Inc., a leading manager of comprehensive wound care treatment centers that offer wound care and hyperbaric oxygen therapy, today announced the completion of the acquisition of CFWH by Sverica International, a leading private equity firm, for approximately $41 million.

24 Dec 2010

Gold-coated liposomes could make chemotherapy more effective without harmful side effects

University of Arizona researchers may have found a way to deliver chemotherapeutic drugs to cancer tissues in controlled doses without harming healthy body cells.

24 Dec 2010

New derivation of stem cells from fat cells hold promise for therapeutic, cosmetic benefits

Two studies appearing in the current issue of Cell Transplantation 19(10) discuss stem cells derived from adipose (fat) cells and their potential use in plastic surgery and tissue reconstruction. The studies are now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ .

24 Dec 2010

MigreLief releases safe, proven effective supplement for children with migraines

MigreLief, the first name in migraine prevention, releases a safe and proven effective supplement for children of all ages: Children's MigreLief.

24 Dec 2010

Over 36,000 people visit interactive infection research exhibition in 2010

The travelling exhibition organised by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) and the Robert Koch Institute (RKI), "Humans and Microbes - Robert Koch's Legacy and Modern Infection Research", has already proved to be a visitor magnet during its very first year. In total, the interactive exhibition attracted more than 36,000 visitors at its three ports of call (Berlin, Bonn and Würzburg), including 400 school classes.

23 Dec 2010

$Herbal pain medication gets fractured runner back running again$

Herbal pain medication gets fractured runner back running again

Debilitating injuries can impact quality of life long after the injury has occurred and healed, producing long-term pain and limited mobility. Individuals recuperating from a surgery or other procedure may want explore different options to getting back on their feet after an injury.

23 Dec 2010

Values-based approach for making more effective New Year's Resolutions

Dr. Richard Blonna, author, life coach, and stress management expert, offers a simple, values-based approach for making more effective New Year's Resolutions.

23 Dec 2010

Arsenic agent for leukemia beneficial in treating medulloblastoma, Ewing's Sarcoma

Researchers at the Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown University Medical Center, have found that an arsenic-based agent already FDA-approved for a type of leukemia may be helpful in another hard-to-treat cancer, Ewing's Sarcoma (ES). The research, based on animal studies, also suggests the drug might be beneficial in treating medulloblastoma, a highly malignant pediatric brain cancer.

23 Dec 2010

Myrexis commences Azixa controlled two-arm Phase 2b clinical study in GBM

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it has initiated a controlled two-arm Phase 2b clinical study of Azixa (verubulin) as a front-line treatment for glioblastoma multiforme (GBM).

23 Dec 2010

U.S. Physical Therapy acquires mid-Atlantic six clinic physical therapy group

U.S. Physical Therapy, Inc., a leading national operator of outpatient physical therapy clinics, has acquired a majority interest in a six clinic physical therapy group located in the mid-Atlantic region. The practice presently sees approximately 55,000 patient visits per year and produces approximately $4.8 million in annual revenue.

23 Dec 2010

GE Healthcare announces completion of tender offer for Clarient

GE Healthcare, a unit of General Electric Company announced today that it has completed the tender offer by GE's wholly owned subsidiary, Crane Merger Sub, Inc., for all outstanding shares of common and preferred stock of Clarient Inc., a leading player in the fast-growing molecular diagnostics sector. Clarient provides pathologists and oncologists with access to key diagnostic tests that shed light on the complex nature of various cancers.

23 Dec 2010

Research: Arsenic trioxide may benefit individuals with connective brain tumors

Arsenic is usually thought of as a poison. Despite this, it has been used in medicine for over 2000 years, and the arsenic compound arsenic trioxide (ATO) is FDA approved for the treatment of acute promyelocytic leukemia.

23 Dec 2010

New method predicts outcome of bleaching treatment for teeth

Researchers at the University of Granada have developed a new method for predicting the precise shade that a bleaching treatment will bring about for a patient's teeth.

23 Dec 2010

Therapy News and Research

Free nicotine patches to help smokers quit this New Year

Patients unresponsive to anti-anemia drug have higher risk of cardiovascular disease, death

International reference standards for use of bone turnover markers in clinical studies recommended

Myrexis initiates controlled two-arm Azixa Phase 2b clinical study in glioblastoma multiforme

Biglycan protein offers potential therapy for muscular dystrophy

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Stem cell therapy helps patient with diabetes gangrene recover from foot ulcer: ICMS conference

Sverica International acquires Center for Wound Healing

Gold-coated liposomes could make chemotherapy more effective without harmful side effects

New derivation of stem cells from fat cells hold promise for therapeutic, cosmetic benefits

MigreLief releases safe, proven effective supplement for children with migraines

Over 36,000 people visit interactive infection research exhibition in 2010

Herbal pain medication gets fractured runner back running again

Values-based approach for making more effective New Year's Resolutions

Arsenic agent for leukemia beneficial in treating medulloblastoma, Ewing's Sarcoma

Myrexis commences Azixa controlled two-arm Phase 2b clinical study in GBM

U.S. Physical Therapy acquires mid-Atlantic six clinic physical therapy group

GE Healthcare announces completion of tender offer for Clarient

Research: Arsenic trioxide may benefit individuals with connective brain tumors

New method predicts outcome of bleaching treatment for teeth

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News